Latest News & Events
PARTNERSHIP AXENIS / PHENOMIN-CIPHE partnership: integrated know-how | Dec. 12, 2017
NEWS Blastocyst genotyping- A new approach to limit the number of animals used in research. | Dec. 6, 2017
SYMPOSIUM ComTech 2018 - Lyon, France | January 25, 2018
CONGRESS Toulouse Onco Week 2018 - Toulouse, France | February 3 - 7, 2018
What PHENOMIN is
PHENOMIN is founded by 3 major national nodes: the Institut Clinique de la Souris (ICS, Illkirch), the Transgenesis and Archiving of Animal Models (CDTA-SEAT-CIPA, Orléans, Villejuif) and the Centre for Immunophenomics (CIPHE, Marseille) that are devoted to serve the French community for the usage of mouse models. PHENOMIN constitutes a unique distributed resource for the creation, the care, the phenotyping, the distribution and archiving of animal models for academics and private corporations.
PHENOMIN will help the scientific community to:
- Improve the knowledge of the mammalian genome by deciphering the function of genes in integrated processes.
- Identify and understand the variations in the genome at the origin of diseases.
- Discover new opportunities for the innovation and development of therapies and of drugs in order to meet the needs of the society.
PHENOMIN, as a large scale national infrastructure for Biotechnology and Health, will primarily provide services for all French laboratories and also be a major player in the international strategic phenogenomics effort. To this end, PHENOMIN contributes to Infrafrontier and the ESFRI-identified pan-European infrastructure for functional genomics.
PHENOMIN will also participate to the International Mouse Phenotyping Consortium (IMPC) and, owing to its tight connection with the Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) at Illkirch and the Centre d'Immunologie de Marseille-Luminy, will be able to provide a major contribution to the goals of the IMPC. PHENOMIN's involvement in the IMPC will fulfill a key item of the the National Alliance for life sciences and health (AVIESAN) strategic plan that consists in applying mouse genetics to analyze the mechanisms of disease and to use this knowledge for advancing fundamental research and human health (AVIESAN report on the use and needs of mouse models in the French scientific community, 2010).